Apellis(US:APLS) Globenewswire·2026-02-24 12:05Core Insights - Apellis Pharmaceuticals reported its fourth quarter and full year 2025 financial results, highlighting significant progress and a strong foundation for future growth [1][2]. Financial Performance - Full-year 2025 net product revenues reached $689 million, with SYFOVRE generating $587 million and EMPAVELI contributing $102 million [6][10]. - Total revenue for Q4 2025 was $199.9 million, compared to $212.5 million in Q4 2024, while total revenue for the full year was $1.0 billion, up from $781.4 million in 2024 [9][10]. - The company reported a net loss of $58.9 million for Q4 2025, compared to a net loss of $36.4 million in Q4 2024, but achieved a net income of $22.4 million for the full year, a significant improvement from a net loss of $197.9 million in 2024 [10][11]. Product Highlights - SYFOVRE, the first approved therapy for geographic atrophy (GA), maintained a market share of approximately 60% and delivered around 102,000 doses in Q4 2025 [7][14]. - EMPAVELI showed strong momentum with a successful launch in C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN), achieving over 5% penetration of the U.S. patient population [7][15]. - A regulatory submission for a prefilled syringe of SYFOVRE is planned for the first half of 2026, and pivotal trials for EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF) are underway [6][7]. Research and Development - The company is advancing its pipeline, including a Phase 2 study of SYFOVRE combined with APL-3007, with topline data expected in 2027 [7][8]. - Apellis is also progressing pre-clinical research on APL-9099, a potential one-time treatment using base editing technology, with an IND submission planned for the second half of 2026 [8]. Cash Position - As of December 31, 2025, Apellis had cash and cash equivalents of $466 million, an increase from $411 million in 2024, and expects this to be sufficient to fund operations to profitability [11][12].